The stakes of the question could hardly be higher. Gliomas, tumors that arise from the glial cells that support and protect neurons, account for roughly 26 percent of all brain tumors and 80 percent of malignant ones. Under the World Health Organization’s classification system, grades 1 and 2 are considered low-grade gliomas, while grade 4 corresponds to glioblastoma, IDH wild-type — the aggressive, treatment-refractory form. The clinical gulf between the two categories is enormous. Patients with glioblastoma who receive the full arsenal of surgery, radiation and the chemotherapy drug temozolomide survive a median of only about 17 months; without any treatment, survival drops to roughly three months. Low-grade glioma, by contrast, carries a median survival of about seven years. This stark difference is precisely what made low-grade glioma such a valuable comparator in the new study: it shares an organ and a cell of origin with glioblastoma but responds far better to treatment, and it shows no meaningful sex difference in outcome.

That sex difference — or the absence of one — sits at the heart of the puzzle the researchers set out to solve. Overall outcomes in glioblastoma are grim for both men and women, yet the picture is not symmetrical. Women respond better to temozolomide, the standard of care, than men do; even so, the five-year survival rate among females with glioblastoma remains below 10 percent. In low-grade glioma, by contrast, sex is not associated with survival at all, despite a slightly higher incidence among males. Known sex-specific molecular features, such as the higher frequency of MGMT promoter hypermethylation in female tumors, explain only a fraction of the gap. The team therefore reasoned that comparing glioblastoma against low-grade glioma within each sex — rather than against healthy brain tissue — would isolate the regulatory changes specific to the resistant, late-stage disease, and reveal whether those changes themselves differ between men and women.

To do this, the group turned to gene regulatory networks: computational models that map which transcription factors — the proteins that switch genes on or off by binding to regulatory DNA — exert control over which target genes, with weighted connections reflecting the strength of evidence for each relationship. The researchers used an algorithm called PANDA, or Passing Attributes between Networks for Data Assimilation, which employs message passing to reconcile three distinct data sources: a prior network built from transcription factor binding motifs cataloged in the CIS-BP database and mapped onto regulatory regions of the human genome; protein-protein interaction data from the GRAND database; and gene co-expression measured within each patient group. Starting from RNA sequencing data in The Cancer Genome Atlas — 153 glioblastoma samples, 53 from women and 100 from men, and 652 low-grade glioma samples, 273 from women and 379 from men — the team built four separate networks, one each for female and male glioblastoma and female and male low-grade glioma, normalizing the raw counts with the voom method into log2-counts per million and restricting the analysis to protein-coding genes. In the female networks, prior weights for Y-chromosome transcription factors were set to zero.

From these networks the researchers computed a targeting score for every gene — the sum of all incoming regulatory edge weights — and ranked the genes within each group. Differences between those rankings, a quantity the team calls differential targeting, revealed which genes come under new or intensified transcription factor control in one condition compared with another. Pathway enrichment was then assessed with the fgsea algorithm against the Molecular Signatures Database canonical pathway collection, using a false discovery rate threshold of 0.05. A pathway was counted as female-specific to glioblastoma only if it was enriched in the comparisons of female glioblastoma against both male glioblastoma and female low-grade glioma, but not in the sex comparison within low-grade glioma, where no clinical sex difference exists. Two additional tools deepened the analysis. MONSTER models the transition between two networks as a matrix equation, estimating a transition matrix whose largest off-diagonal weights identify the transcription factors driving the rewiring between disease states. BLOBFISH searches the networks for subnetworks in which the same regulators jointly control multiple groups of genes, retaining only statistically supported connections. Every key finding was then re-tested in an independent cohort, REMBRANDT.

The results in women were strikingly coherent. Female glioblastoma showed increased targeting of hypoxia pathways and of the programs hypoxia is known to drive: aerobic glycolysis and glycan biosynthesis within carbohydrate metabolism, powered by genes such as LDHA, PGK1, GAPDH, HK3 and PKM; immune processes including neutrophil degranulation and lysosomal pathways; and extracellular matrix and collagen remodeling. One enriched pathway initially appeared puzzling — renal cell carcinoma — but its gene content resolved the mystery. The signal was driven by the angiogenesis genes VEGFA and PDGFRA, an entire glycolysis program, and VHL, the tumor suppressor responsible for tagging HIF1A for destruction. In other words, the brain tumor had mobilized the very circuitry that kidney cancers use to thrive in low oxygen. MONSTER analysis reinforced the picture: 249 transcription factors had rewired their targeting between low-grade glioma and glioblastoma in women, compared with only 12 in men. Of these, 240 were exclusive to females, and among them were three regulators of the hypoxia response — CXXC5, EGFR and, most consequentially, HIF1A itself — alongside more than a dozen controllers of innate immunity.

Men told a completely different story. The pathways placed under altered control in male glioblastoma were the spliceosome — the molecular machine that cuts and rejoins RNA transcripts — and androgen receptor signaling. The differential targeting touched genes across the spliceosomal E, pre-B, B, Bact, B, C and P complexes, indicating a broad reorganization of RNA processing rather than a change at a single point. This finding dovetails with earlier observations that different transcription factors target the spliceosome in the healthy brain tissue of men and women, and with evidence that alternative splicing can undermine treatment response independent of hypoxia by reshaping transcription factor activity, fueling angiogenesis and easing tumor cell migration. In male glioblastoma, in other words, resistance appears to route through RNA processing and androgen signaling rather than through oxygen sensing at all.

The most distinctive result, however, lay in how these pathways talk to each other. In the female glioblastoma networks, the same transcription factors were found to co-regulate hypoxia genes together with genes in carbohydrate metabolism, the extracellular matrix and immune processes — an interlocking regulatory web in which a single controller reaches across multiple disease programs at once. Male networks showed co-regulation too, but of a different architecture: mRNA splicing was linked with metabolism, extracellular matrix and immune pathways, while hypoxia sat entirely outside the web. When the team repeated the analysis in the REMBRANDT cohort, the canonical hypoxia result did not fully replicate, but the female-specific pattern re-emerged through a back door: genes targeted by HIF1A within the renal cell carcinoma pathway, particularly BIRC7, PDGFRA and VEGFA — all established downstream effectors that drive tumor progression under hypoxia — were co-regulated with the same pathway categories in women only, while the androgen receptor co-regulation seen in TCGA males did not reappear.

The biology behind these patterns is well supported by prior work. Hypoxia is a known driver of chemotherapy resistance: low oxygen forces metabolic reprogramming toward glycolysis, and in glioblastoma specifically HIF1A promotes angiogenesis, glucose metabolism and cell migration. Hypoxia also enables immune evasion through multiple mechanisms, and the neutrophil degranulation pathway flagged in the female tumors has been implicated in the necrosis and poorer survival that characterize aggressive disease. The new findings mesh neatly with earlier sex-difference research. One prior study found that temozolomide response in women, but not men, was linked to reduced integrin signaling — and integrins are known to regulate HIF1A expression and to remodel the extracellular matrix under hypoxic conditions. Another reported that granulocytic myeloid-derived suppressor cells, immunosuppressive cells that blunt anti-tumor immunity, are elevated in female mice with glioblastoma but not in males. A third showed that male mice respond better to anti-PD-1 immunotherapy, possibly because PD-L1, the molecular brake that the therapy targets, is overexpressed in hypoxic tumor environments.

The practical implication is that drugs already built to block HIF signaling in kidney cancer deserve testing as sex-specific therapy for women with glioblastoma, while men may require an entirely different strategy aimed at RNA splicing or androgen signaling. The authors are careful about the limits of their approach: the network method cannot say whether a regulatory relationship is activating or inhibitory, the data were collected at a single time point so causality must rest on prior knowledge rather than causal models, the tumors were classified under older WHO schemes that may have misclassified some cases, and both cohorts skew heavily toward white participants, with female glioblastoma samples forming the smallest group. Still, the study — funded by the National Institutes of Health and published open access — reframes glioblastoma treatment resistance as a problem of regulatory architecture that differs by sex, and it hands oncologists a concrete, testable shortlist of targets, with the oxygen sensor HIF1A at the top of the list for women.

Esophageal squamous cell carcinoma remains a leading cause of cancer mortality. With its increasing prevalence globally, understanding the molecular mechanisms underpinning its aggressive nature is of paramount importance. Traditional treatments, including surgery, chemotherapy, and radiotherapy, often encounter the formidable barrier of treatment resistance, which significantly hampers patient outcomes. The research presented by Lei and colleagues offers fresh perspectives on overcoming this challenge.

Central to the study is the NF-κB signaling pathway, a crucial regulator of immune and inflammatory responses. This pathway has often been implicated in cancer progression and resistance to cancer therapies. Lei et al. have methodically analyzed the expression levels of various proteins within the NF-κB signaling cascade, revealing a marked activation in GSDME-low ESCC cells, which correlates with heightened resistance to radiotherapy. The significance of NF-κB in cancer biology cannot be overstated, as it appears to coordinate various cellular processes, including proliferation, apoptosis, and metastasis.

GSDME (Gasdermin E) is a member of the gasdermin family, which has emerged as a key player in cancer biology. Recent studies have shown that GSDME acts as a notable regulator of cell death mechanisms. In the context of ESCC, low levels of GSDME expression create an environment where cells become increasingly reliant on NF-κB signaling. This dependence suggests that tumor cells can adopt alternative survival strategies when faced with therapeutic pressures, such as radiation exposure, complicating treatment efforts.

The methodological approach undertaken by the researchers involved a series of in vitro experiments that aimed to delineate the role of the NF-κB pathway in GSDME-low ESCC cells. Using both molecular biology techniques and sophisticated genetic manipulation, they were able to inhibit NF-κB activity and then assess the resulting impact on cell survival upon radiation exposure. The insights gained from these experiments demonstrate that targeting the NF-κB pathway could be a viable strategy to enhance the effectiveness of radiotherapy in GSDME-low ESCC patients.

The findings of this research highlight the importance of personalized medicine in oncology. By identifying specific biomarkers, such as GSDME expression levels, clinicians may one day predict which patients are most likely to benefit from certain treatment modalities. This proactive approach could minimize unnecessary side effects and gear treatments toward those most likely to succeed. Ultimately, Lei et al.’s work serves as a catalyst for future studies aimed at exploring combination therapies that integrate NF-κB inhibitors with conventional radiation treatment.

The implications of this study extend beyond esophageal cancer alone. The insights gleaned from the NF-κB pathway could potentially apply to a variety of malignancies characterized by similar resistance mechanisms. Indeed, as further research uncovers the multifaceted roles of GSDME and NF-κB in different cancer types, there is a growing hope that treatments informed by molecular signatures will soon become the standard rather than the exception.

In conclusion, the activation of the NF-κB signaling pathway in GSDME-low esophageal squamous cell carcinoma cells represents a significant finding in the ongoing battle against treatment resistance in cancer. Lei et al.’s research lays a critical foundation for future investigations aimed at unraveling the complexities of this disease, providing valuable insights into how therapeutic targets can be leveraged to improve patient outcomes. As the scientific community continues to delve deeper into the mechanisms of cancer biology, studies like this highlight the importance of a multifaceted approach to treatment, one that combines innovative research with practical clinical applications.

In the fight against cancer, understanding the molecular intricacies of signaling pathways offers renewed hope. The work of Lei et al. demonstrates just how essential it is to keep pushing the boundaries of what we know about cancer biology. As these findings spur further inquiry, the promise of more effective therapies tailored to individual patients draws closer to reality. This transformative potential should encourage collaborative efforts across the spectrum of cancer research and treatment development, ultimately leading to a future where treatment approaches are as dynamic as the diseases they aim to eradicate.

There’s no doubt that the landscape of cancer treatment is shifting, and understanding the role that pathways like NF-κB play in resistance will be pivotal in this evolution. The road ahead is filled with challenges, but with studies such as this, we are inching closer to more effective, personalized cancer therapies that could ultimately improve survival rates and quality of life for countless patients around the world.

As the medical community digests these findings, follow-up studies will be crucial to explore the broader implications of these discoveries. Researchers will need to investigate the potential for combining NF-κB inhibitors with existing therapies in clinical trials, assessing both efficacy and safety. The implications for treatment protocols are vast and largely uncharted, but the potential rewards are immense, offering hope of a more successful trajectory for patients combating this tenacious disease.

In a world where cancer continues to present daunting challenges, every small win counts. The research led by Lei et al. illuminates a new direction for investigating therapeutic strategies, fostering a sense of optimism and urgency within the scientific community. The combination of rigorous research efforts and groundbreaking discoveries stands to reshape the future of cancer treatment as we know it.

Now more than ever, the collective efforts of scientists, researchers, and clinicians are essential in transforming these findings into concrete clinical applications. The battle against cancer is a marathon, not a sprint, and it is through these kinds of innovative studies that we will be equipped with the tools to extend and enhance lives. The journey is ongoing, but with each breakthrough, we move closer to a world where cancer may one day be a readily manageable condition.

Subject of Research: Activation of NF-κB signaling pathway in GSDME-low esophageal squamous cell carcinoma cells enhances radioresistance.

Article Title: Activation of NF-κB signaling pathway in GSDME-low esophageal squamous cell carcinoma cells enhances radioresistance.

Article References:

Lei, L., Zhao, Y., Wang, B. et al. Activation of NF-κB signaling pathway in GSDME-low esophageal squamous cell carcinoma cells enhances radioresistance. J Transl Med (2026). https://doi.org/10.1186/s12967-025-07635-4

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07635-4

Keywords: NF-κB, GSDME, esophageal squamous cell carcinoma, radioresistance, cancer therapy.